Department of Surgery, Westchester Medical Center, School of Medicine, New York Medical College, Valhalla, NY, USA.
Einstein Healthcare Network, Philadelphia, PA, USA.
Womens Health (Lond). 2022 Jan-Dec;18:17455057221097554. doi: 10.1177/17455057221097554.
The incidence of breast cancer following solid organ transplantation is comparable to the age-matched general population. The rate of de novo breast cancer following liver transplantation varies. Furthermore, there is limited information on the management and outcomes of breast cancer in liver transplant recipients. We aim to evaluate the impact of liver transplantation on breast cancer surgery outcomes and compare the outcomes after breast cancer surgery in liver transplant recipient in transplant versus non-transplant centers.
National Inpatient Sample database was accessed to identify liver transplant recipient with breast cancer. Mortality, complications, hospital charges, and total length of stay were evaluated with multivariate logistic regression testing. Weighted multivariate regression models were employed to compare outcomes at transplant and non-transplant centers.
Ninety-nine women met inclusion criteria for liver transplantation + breast cancer and were compared against women with breast cancer without liver transplantation (n = 736,527). Liver transplantation + breast cancer had lower performance status as confirmed via higher Elixhauser Comorbidity Index (20.5% vs 10.2%, p < 0001). There were significantly more complications in the liver transplantation cohort when compared to the non-liver transplant recipient (15.0% vs 8.2%, p = 0.012). However, on multivariate analysis, liver transplantation was not an independent risk factor for post-operative complications following breast cancer surgery (odd ratio, 1.223, p = 0.480). Cost associated with breast cancer care was significantly higher in those with liver transplantation (2.621, p < 0.001). Breast conservation surgery in liver transplantation had shorter length of stay as compared to breast cancer alone (odds ratio, 0.568, p = 0.027) in all hospitals.
Liver transplantation does not increase short-term mortality when undergoing breast cancer surgery. Although there were significantly more complications in the liver transplantation cohort when compared to the non-liver transplant recipient (15.0% vs 8.2%, p = 0.012), on multivariate analysis, liver transplantation was not an independent risk factor for postoperative complications following breast cancer surgery. Breast cancer management in liver transplant recipient at non-transplant centers incurred higher charges but no difference in complication rate or length of stay when compared to transplant centers.
实体器官移植后乳腺癌的发病率与年龄匹配的一般人群相当。肝移植后新发乳腺癌的发生率各不相同。此外,关于肝移植受者乳腺癌的管理和结局的信息有限。我们旨在评估肝移植对乳腺癌手术结局的影响,并比较肝移植受者在移植中心和非移植中心接受乳腺癌手术后的结局。
利用国家住院患者样本数据库确定患有乳腺癌的肝移植受者。使用多变量逻辑回归检验评估死亡率、并发症、住院费用和总住院时间。采用加权多变量回归模型比较移植中心和非移植中心的结果。
99 名女性符合纳入标准,进行了肝移植+乳腺癌治疗,并与未进行肝移植的乳腺癌女性(n=736527 名)进行了比较。肝移植+乳腺癌患者的表现状态较差,这一点通过更高的 Elixhauser 合并症指数得到了证实(20.5%对 10.2%,p<0.001)。与非肝移植受者相比,肝移植组的并发症明显更多(15.0%对 8.2%,p=0.012)。然而,多变量分析显示,肝移植并不是乳腺癌手术后发生术后并发症的独立危险因素(比值比,1.223,p=0.480)。肝移植患者乳腺癌相关治疗费用明显较高(2.621,p<0.001)。在所有医院中,与单独乳腺癌相比,肝移植患者行乳腺癌保乳手术的住院时间更短(比值比,0.568,p=0.027)。
肝移植不会增加乳腺癌手术的短期死亡率。尽管与非肝移植受者相比,肝移植组的并发症明显更多(15.0%对 8.2%,p=0.012),但多变量分析显示,肝移植并不是乳腺癌手术后发生术后并发症的独立危险因素。与移植中心相比,非移植中心的肝移植受者乳腺癌管理费用较高,但并发症发生率和住院时间无差异。